Table 8: Summary of Study Characteristics: Model 2.

Study, Design (N), Country	Inclusion Criteria†	Intervention Group			Setting	Control¶	Outcomes#	Length of FU (Freq. of FU)**	Study Quality
		Care provider	Types of Interventions Delivered	Method of Care Delivery
MODEL OF CARE: 2. At least a pharmacist and primary care physician
Choe, et al, 2005 (22) RCT (N = 80) USA	T2DM, HbA1c ≥8.0%, age ≤70 y [excluded patients with severe co-morbidity)	Pharm, PCP	Diabetes education Pharmacotherapy management (with prior approval by PCP) Promotion of self-care, behavioural modification or problem-solving skills Integration of pharmacist within primary care Case management or care coordination	Clinicvisits, telephone follow-up (Individual)	Primary care clinic	Usual care (by PCP)	Primary: HbA1c Secondary: process measures (LDL, retinal exam, urine microalbumin-uria screening, monofilament testing for neuropathy)	12 months (monthly)	High
McLean, et al, 2008 (18) RCT (N = 227) Canada	Diabetes, adults, BP >130/80 mm Hg on 2 screening visits 2 weeks apart	Pharm, PCP, dRN	Diabetes education (structured program) Pharmacotherapy management (with prior approval by PCP) Promotion of self-care, behavioural modification or problem-solving skills Integration of pharmacist within primary care CVD risk reduction counselling	Clinic visits (Individual)	Community	Usual care (by RN or Pharm) + minimal education	Primary: BP Secondary: BPtargets (≤130/80 mm Hg), anti-hypertensive drug therapy, angiotensin-converting enzyme inhibitor	6 months (every 6 weeks)	High
Rothman, et al, 2005 (17) RCT (N = 217) USA	T2DM, age ≥ 18y, HbA1c ≥8%, English-speaking, life expectancy 〉 6 months	Pharm (CDE), PCP	Structured diabetes education Pharmacotherapy management Promotion of self-care, behavioural modification or problem-solving skills Integration of pharmacist within primary care Case management or care coordination Clinical registry tracking for uncontrolled clinical outcomes	Clinic visits, telephone or in-person follow-up (Individual)	Primary care clinic	Usual care (by PCP)	Primary: BP, HbA1c, aspirin use at 6 and 12 months Secondary: diabetes knowledge, satisfaction, use of clinical services, adverse events	12 months (every 2-4 weeks)	High

^*RCT, randomized controlled trial;

^†BP, blood pressure; CV, cardiovascular; HbA1c, glycosylated hemoglobin; mo, months; PCP, primary care physician; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; y, years;

^‡NA, not available (contacted study author; data unavailable); NR, not reported;

^§CDE, certified diabetic educator; D, diabetologist; dRN, diabetes specialist nurse; E, endocrinologist; HCP, health care professional; MD, physician (unspecified specialty); PCP, primary care physician; Pharm, pharmacist; Physio, physiotherapist; RD, registered dietician; RN, registered nurse; PCP, primary care physician; MD, physician; PCP, primary care physician; Pharm, pharmacist; RN, nurse; blood pressure; FBG, fasting blood glucose; HDL, high-density lipoprotein; HRQoL, health-related quality of life; LDL, low-density lipoprotein cholesterol;

^**FU, follow-up;

^††No specification of primary or secondary outcomes.